Progress in the studies of alpha1-receptor blocker for benign prostatic hyperplasia.
- Author:
Yinghao SUN
1
Author Information
1. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. yhsun@smmu.edu.cn
- Publication Type:Journal Article
- MeSH:
Adrenergic alpha-1 Receptor Antagonists;
Adrenergic alpha-Antagonists;
adverse effects;
pharmacokinetics;
therapeutic use;
Humans;
Male;
Prostatic Hyperplasia;
drug therapy;
Receptors, Adrenergic, alpha-1;
analysis
- From:
National Journal of Andrology
2004;10(7):483-485
- CountryChina
- Language:Chinese
-
Abstract:
Benign prostatic hyperplasia (BPH) is a common senile disease, and its main clinical manifestation is lower urinary tract symptom (LUTS), which has long been afflicting old male patients. Previous study showed that alpha1-receptor in the prostate was involved in the development of LUTS. At present, alpha1-receptor blocker is generally accepted as a choice drug for treating BPH and relieving LUTS. The article reviews the tissue distribution of alpha1-receptor and clinical application of alpha1-receptor blocker.
